Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026
Key Highlights
- ➤Atea (AVIR) will report Q3 2026 results and provide a business update November 9.
- ➤Phase 3 program evaluates bemnifosbuvir and ruzasvir for hepatitis C treatment.
- ➤AT-587 is in Phase 1 development for hepatitis E treatment.
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2026, and to provide a business update.
To access the live conference call, participants may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. An archive of the audio webcast will be available on Atea’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.
Get started
Create a free account to read the full story.
